On November 3, 2026, Illumina is trading 4.4% higher at $236.56, with its SG-INSIGHT selection a possible catalyst; reports do not confirm it drove the intraday rise.
- The whole-genome sequencing award followed an international competitive tender and is part of Phase III of the National Precision Medicine programme, which aims to cover around 450,000 people.
- The move follows a sharp post-earnings selloff as investors focused on China-related challenges and growth concerns, despite raised full-year guidance.